Takeda Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd/ US8740602052 /
TAK
|
9/29/2023 9:59:57 PM
|
Chg.
-0.12
|
Volume |
Bid- |
Ask- |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
15.48USD
|
-0.74%
|
30,488
Turnover: 472,516.31 |
-Bid Size: - |
-Ask Size: - |
46.09 bill.USD |
- |
- |
Business description
Located in Osaka, Japan, Takeda (TYO: 4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine.
Management board & Supervisory board
| CEO |
| Christophe Weber |
| Management board |
| Costa Saroukos, Dr. Andrew S. Plump, Dr. Masato Iwasaki, Gerard Greco, Giles Platford, Julie Kim, Koki Sato, Lauren Duprey, Marcello Agosti, Milano Furuta, Mwana Lugogo, Rajeev Venkayya, Ramona Sequeira, Ricardo Marek, Takako Ohyabu, Teresa Bitetti, Thomas Wozniewski, Yoshihiro Nakagawa |
| Supervisory board |
| Christophe Weber, Costa Saroukos, Dr. Andrew Plump, Dr. Masato Iwasaki, Emiko Higashi, Ian Clark, Jean-Luc Butel, Koji Hatsukawa, Masahiro Sakane, Masami Iijima, Michel Orsinger, Olivier Bohuon, Shiro Kuniya, Steven Gillis, Toshiyuki Shiga, Yoshiaki Fujimori |
Company data
| Name: |
Takeda Pharmaceutical Company Ltd. |
| Address: |
1-1, Nihonbashi-Honcho 2-Chome,Chuo-ku, Tokyo 103-8668, Japan |
| Phone: |
+81-3-3278-2306 |
| Fax: |
+81-3-3278-2268 |
| E-mail: |
-
|
| Internet: |
www.takeda.com/ |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
3/31 |
| Free Float: |
- |
| IPO date: |
- |
Company calendar
|
CW 43 | 10/26/2023
Interim Report 2nd Quarter/6 Months
|